IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner

Citations Over TimeTop 10% of 2016 papers

Abstract

Hepatic fibrosis in nonalcoholic steatohepatitis (NASH) and cirrhosis determines patient prognosis; however, effective treatment for fibrosis has not been established. Oxidative stress and inflammation activate hepatic stellate cells (HSCs) and promote fibrosis. In contrast, cellular senescence inhibits HSCs' activity and limits fibrosis. The aim of this study was to explore the effect of IGF-I on NASH and cirrhotic models and to clarify the underlying mechanisms. We demonstrate that IGF-I significantly ameliorated steatosis, inflammation, and fibrosis in a NASH model, methionine-choline-deficient diet-fed db/db mice and ameliorated fibrosis in cirrhotic model, dimethylnitrosamine-treated mice. As the underlying mechanisms, IGF-I improved oxidative stress and mitochondrial function in the liver. In addition, IGF-I receptor was strongly expressed in HSCs and IGF-I induced cellular senescence in HSCs in vitro and in vivo. Furthermore, in mice lacking the key senescence regulator p53, IGF-I did not induce cellular senescence in HSCs or show any effects on fibrosis. Taken together, these results indicate that IGF-I induces senescence of HSCs, inactivates these cells and limits fibrosis in a p53-dependent manner and that IGF-I may be applied to treat NASH and cirrhosis.

Related Papers

• → Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease(2008)250 cited
• → Are Steatosis and Steatohepatitis Triggers of Hepatic Fibrogenesis(2013)2 cited
• → 1232 XANTHOHUMOL IMPROVES GLUCOSE TOLERANCE AND INHIBITS HEPATIC STEATOSIS, INFLAMMATION AND FIBROGENESIS IN A MURINE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS(2012)
• → Faculty Opinions recommendation of Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis.(2008)
• → STUDY OF CELL MODELS OF HEPG2 STEATOSIS AND STEATOHEPATITIS VIABILITY(2023)